Heinz Ludwig, MD, and Meral Beksac, MD, discuss identifying high-risk myeloma patients and improving treatment strategies. They explore parameters for defining high-risk disease, the insufficiency of current risk definitions, and the debate on cytogenetic abnormalities. The speakers also delve into the identification of high-risk patients using reliable tools and discuss treatment strategies including quadriplet therapy and CAR-T. Furthermore, they highlight the significance of the microenvironment in managing high-risk myeloma and the need for further research.
